Citrobacter Freundii Complex: Health Concerns & Treatment

The Citrobacter freundii complex is a group of closely related bacterial species that have shifted from being considered harmless environmental organisms to recognized hospital-acquired pathogens over the past few decades. These bacteria are responsible for urinary tract infections, bloodstream infections, wound infections, and, in newborns, a particularly dangerous form of meningitis that can lead to brain abscesses.¹ What makes the complex especially worrisome is the speed at which it picks up antibiotic resistance genes, sometimes rendering even last-resort drugs ineffective.

What the Complex Actually Includes

The name “Citrobacter freundii complex” is a practical label used in clinical laboratories to group together several Citrobacter species that look almost identical under standard testing. The complex includes C. freundii itself along with species such as C. braakii, C. youngae, C. werkmanii, and several others. Routine lab methods often cannot reliably tell these species apart, so clinicians and microbiologists lump them together. That grouping is convenient but comes at a cost: it can obscure which species within the complex are driving resistance or causing specific types of infection.² Newer identification tools, particularly a technology called MALDI-TOF mass spectrometry, have improved the picture. In one evaluation, MALDI-TOF correctly identified about 95% of Citrobacter strains to the species level, outperforming traditional biochemical methods in speed and accuracy.³

The distinction matters for treatment. Different species within the complex carry different resistance profiles and virulence traits. C. braakii isolates, for example, have been found to carry capsule-building genes similar to those seen in Salmonella, while certain C. freundii strains pick up iron-scavenging gene clusters that enhance their ability to survive in the human body.⁴ Treating the complex as one undifferentiated bug risks missing those differences.

Where These Bacteria Live and How They Reach Patients

Members of the C. freundii complex are naturally found in soil, water, sewage, and the gastrointestinal tracts of humans and animals. For most healthy people, carrying these organisms in the gut causes no symptoms. The trouble starts when the bacteria reach a site they should not be, such as the bloodstream, urinary tract, or surgical wound, typically in patients whose defenses are already compromised. Hospital settings are the primary stage for serious infections. The complex is recognized as an increasingly significant group of opportunistic pathogens in healthcare, driven by its remarkable ability to acquire new genetic material through horizontal gene transfer.¹

The food supply also acts as a reservoir. Research on chicken and red meat products in Iran found an alarming prevalence of multidrug-resistant C. freundii, with resistance patterns tied to farming practices and antibiotic exposure in livestock.⁵ That finding fits a broader pattern: antibiotic use in agriculture selects for resistant strains that can then move into the human population through the food chain or environmental contamination. It is the kind of issue that One Health researchers point to when arguing that antibiotic resistance cannot be solved by looking at hospitals alone.

What Infections It Causes

Urinary tract infections are the most common clinical presentation. A hospital-based study found that urinary infections accounted for over half of all Citrobacter-related illness, followed by intra-abdominal infections at about 14%, and surgical site, skin, and respiratory infections each in the single digits.⁶ A notable feature of these infections is that roughly 30% of cases were polymicrobial, meaning Citrobacter was found alongside other bacteria, which tended to prolong hospital stays significantly.

Bloodstream infection, or bacteremia, is less common but more dangerous. A population-based study found that C. freundii complex bloodstream infections primarily affect elderly patients, are often linked to abdominal surgery, and are more frequently polymicrobial compared to C. koseri bloodstream infections.⁷ In one study of C. freundii bacteremia, the mortality rate directly attributable to the infection was about 22%. The factors that independently predicted death were the severity of the underlying disease, septic shock, and the presence of other bacteria in the bloodstream alongside Citrobacter. Patients who underwent therapeutic surgical procedures, such as drainage of an abscess, had a lower mortality rate of roughly 5%.⁸

Another study of bloodstream infections from Enterobacter species and C. freundii found that patients infected with strains resistant to certain cephalosporins or to trimethoprim-sulfamethoxazole, or patients who required mechanical ventilation, faced higher mortality.⁹ The picture that emerges is consistent: the sickest patients, with the most resistant strains, face the worst outcomes.

Neonatal Meningitis and Brain Abscesses

One of the most devastating manifestations of Citrobacter infection occurs in newborns. Citrobacter species are uncommon causes of neonatal meningitis, but when they do infect the central nervous system, they have a pronounced tendency to form brain abscesses.¹⁰ Across case series, roughly 30% of neonates with Citrobacter meningitis die, and about half of survivors sustain some form of lasting neurological damage.¹¹

C. koseri, a related species within the broader Citrobacter genus, is the species most classically associated with neonatal brain abscesses. A case series of four neonates with C. koseri meningitis reported that one developed brain abscesses and another died.¹² C. freundii can cause the same syndrome, though it is reported less frequently. The infection can be acquired vertically, meaning the newborn picks it up from the mother during or around the time of delivery. Treatment typically requires prolonged courses of intravenous antibiotics and, in many cases, neurosurgical intervention to drain abscesses. Even with aggressive treatment, the prognosis remains guarded.

How the Bacteria Arm Themselves Against Antibiotics

The C. freundii complex carries a chromosomal gene called ampC that encodes a type of enzyme capable of breaking down certain antibiotics, particularly cephalosporins. What makes this gene particularly troublesome is that it is inducible: exposure to certain beta-lactam antibiotics actually switches on production of the enzyme. A regulatory gene called ampR controls this process, acting as a kind of molecular switch. In the absence of antibiotics, AmpR represses ampC expression modestly. When beta-lactam antibiotics are present, AmpR flips its role and becomes a positive regulator, boosting enzyme production roughly 11-fold.¹³ The practical consequence is that starting a patient on certain cephalosporins can, paradoxically, trigger the very resistance mechanism that defeats them.

Mutations in ampR can make things worse. Research on extended-spectrum beta-lactamase-producing C. freundii strains found that high AmpR expression was associated with resistance to tazobactam, ampicillin, gentamicin, nitrofurantoin, and cephalosporins. When the researchers deleted the ampR gene entirely, resistance to beta-lactams and aminoglycosides dropped, confirming AmpR’s central role in the resistance network.¹⁴

Beyond this built-in resistance, the complex picks up additional resistance genes on mobile genetic elements like plasmids. Strains carrying carbapenemase genes are the most alarming, because carbapenems are often drugs of last resort. A surveillance study in Germany documented a rising number of Citrobacter species carrying OXA-48-like carbapenemase genes on transferable plasmids, the majority belonging to the IncL plasmid group.¹⁵ Even more concerning are strains that carry multiple carbapenemase genes simultaneously. Whole genome sequencing of a C. freundii strain in China revealed it harbored 16 resistance genes, including both blaKPC-2 and blaNDM-1, two of the most potent carbapenemases known, along with extended-spectrum beta-lactamase and AmpC-type genes.¹⁶ A separate study confirmed another clinical C. freundii isolate co-producing KPC-2 and NDM-1 on distinct plasmids.¹⁷ Strains like these are resistant to virtually every conventional antibiotic.

Why Resistance Spreads So Quickly in This Group

The C. freundii complex is, in some respects, a perfect vehicle for spreading antibiotic resistance. Its genomic plasticity means it can accept foreign DNA readily. The resistance genes it acquires are often carried on plasmids that can transfer between bacterial species, meaning C. freundii can serve as a reservoir that passes dangerous genes to other pathogens like Klebsiella or E. coli. Integrons, genetic structures that capture and rearrange resistance gene cassettes, are present in an estimated 10% of sequenced bacterial genomes and are frequently linked to mobile genetic elements, particularly class 1 integrons, which facilitate horizontal transfer within and between species.¹⁸ C. freundii isolates commonly carry class 1 integrons, making them efficient collectors and distributors of resistance genes across bacterial communities.

The virulence side of the equation follows a similar pattern. A genomic analysis of a C. freundii strain from a sepsis patient in Uganda found that it carried both chromosomal and plasmid-encoded secretion systems used to inject toxins into host cells, along with genes for iron scavenging and biofilm formation.¹⁹ Biofilm formation is especially relevant in clinical settings: bacteria wrapped in a biofilm matrix on a catheter or wound surface are dramatically harder to kill with antibiotics than free-floating cells. A study of 120 C. freundii isolates from urinary tract infections found that 30% formed large colonies with substantial biofilm production, and these were linked to resistance patterns.²⁰

Treatment Challenges and Options

Treating C. freundii complex infections is not straightforward precisely because of the resistance mechanisms described above. The inducible AmpC enzyme means that standard cephalosporins like ceftriaxone or ceftazidime can appear effective in the lab initially but fail in the patient as the bacterium ramps up enzyme production. For this reason, many infectious disease specialists avoid third-generation cephalosporins for serious Citrobacter infections even when the lab report says the strain looks susceptible.

Carbapenems have traditionally been the go-to choice for resistant strains, but the emergence of carbapenemase-producing Citrobacter strains has eroded that option. Newer beta-lactam/beta-lactamase inhibitor combinations offer some hope. Laboratory work on a KPC-2-producing C. freundii strain showed that adding avibactam at a fixed concentration restored the activity of multiple beta-lactam antibiotics, including ceftazidime, cefepime, aztreonam, meropenem, and imipenem.²¹ Ceftazidime-avibactam has become one of the more important tools against KPC-producing organisms, though resistance to it has already been documented, sometimes arising from mutations within the KPC gene itself. Notably, those mutations that confer ceftazidime-avibactam resistance can sometimes restore susceptibility to carbapenems, creating a therapeutic seesaw that clinicians can occasionally exploit.

For strains producing NDM-type carbapenemases, the picture is bleaker. Avibactam does not inhibit NDM enzymes, so ceftazidime-avibactam is ineffective against those strains. Options narrow to drugs like colistin, tigecycline, or the newer cefiderocol, each carrying its own limitations in terms of toxicity, tissue penetration, or emerging resistance. When a C. freundii strain carries both KPC and NDM genes simultaneously, as the strains described earlier do, there are essentially no reliable single-agent options, and clinicians typically resort to combination therapy guided by case-by-case susceptibility testing.

Infection Control in Hospitals

Preventing spread within healthcare facilities relies on the same toolkit used against other resistant gram-negative bacteria: hand hygiene, contact precautions for colonized or infected patients, environmental cleaning, and active surveillance cultures in high-risk units. An outbreak of KPC-producing C. freundii at a tertiary hospital in Miami illustrated this in practice. After identifying a cluster of three cases, the hospital implemented supplementary environmental cleaning and performed terminal cleaning of the affected unit, on top of the infection control bundle already in place. No further cases were identified after those measures.²²

The lesson from that outbreak and others like it is that early detection matters enormously. Because Citrobacter can colonize the gut silently, patients can spread it to surfaces and healthcare workers without anyone realizing until a clinical infection declares itself. Hospitals that perform rectal surveillance swabs on admissions to intensive care units are more likely to catch carbapenemase-producing strains before they cause outbreaks. Rapid molecular tests for carbapenemase genes can return results within hours, allowing infection control teams to act before the bacteria circulate widely.

Bacteriophage Therapy as a Future Option

With conventional antibiotics losing ground, researchers have turned to bacteriophages, viruses that specifically target and kill bacteria, as a potential alternative for multidrug-resistant C. freundii infections. A phage designated CfP1 demonstrated potent activity against clinical C. freundii isolates resistant to up to 12 antibiotics, including penicillins, cephalosporins, carbapenems, and fluoroquinolones. The phage’s lysin enzyme reduced C. freundii counts by over 100-fold and C. koseri counts by over 10,000-fold without needing any chemical pretreatment to breach the bacterial outer membrane.²³

More recent work on a phage called vB_Cf_HW01 showed it could severely disrupt established C. freundii biofilms, reducing live bacterial coverage from about 9% to 3% while dramatically increasing dead cells. In an invertebrate infection model, a single dose of the phage rescued about a third of infected larvae.²⁴ Biofilm disruption is a particularly valuable property, since biofilms protect bacteria from both antibiotics and the immune system, and no currently approved antibiotic reliably penetrates mature biofilms.

Phage therapy for Citrobacter is still in early-stage research; no large clinical trials have been completed, and regulatory frameworks for phage products remain underdeveloped in most countries. But the laboratory results are encouraging enough that compassionate-use phage treatments for pan-resistant gram-negative infections, including Citrobacter, are being reported with increasing frequency. For patients who have genuinely run out of antibiotic options, phages represent one of the few remaining avenues. Whether they can move from individual compassionate-use cases to standardized, widely available treatments is one of the more consequential open questions in infectious disease.

Who Is Most at Risk

The C. freundii complex is overwhelmingly a problem for people with weakened defenses. If you are healthy, living in the community, and not recently hospitalized, your risk of a serious Citrobacter infection is vanishingly small. The typical patient is elderly, has been hospitalized for a prolonged period, has an indwelling catheter or recent abdominal surgery, or has a serious underlying condition such as cancer or organ failure. Bloodstream infections from the complex primarily affect elderly patients either hospitalized or closely connected to healthcare settings.⁷

Premature and low-birth-weight newborns form the other high-risk group, particularly for meningitis and brain abscess. Immunosuppressed patients, including those on chemotherapy or post-transplant immunosuppressive regimens, are also disproportionately affected. For these populations, the combination of impaired immune defenses and frequent antibiotic exposure creates the perfect conditions for resistant Citrobacter strains to take hold. One study of C. freundii bacteremia found that carrying certain resistance genes, specifically blaTEM-1, was an independent risk factor for 28-day mortality, suggesting that in vulnerable patients, the resistance profile of the infecting strain directly influences the chance of survival.²⁵

Iron Scavenging and the High-Pathogenicity Island

One of the subtler ways Citrobacter strains become more dangerous is by stealing iron from the host. Iron is essential for bacterial growth, and the human body actively restricts free iron as a defense mechanism. To overcome this, pathogenic bacteria produce small molecules called siderophores that grab iron from host proteins and shuttle it back to the bacterium. Analysis of clinical Citrobacter isolates found that some C. freundii strains have acquired gene clusters for producing yersiniabactin, a particularly efficient siderophore originally characterized in Yersinia, the genus that includes the plague bacterium. These gene clusters sit on mobile chromosomal elements called ICEkp, and their presence in C. freundii had not been reported before these analyses. C. freundii strains carrying these elements showed diverse pathogenic features, suggesting that the acquisition of iron-scavenging machinery can meaningfully alter how aggressive a strain behaves in the body.⁴ The finding underscores a recurring theme with this organism: its capacity to borrow genetic tools from unrelated bacteria and repurpose them in ways that make infections harder to control.